Abstract Eslicarbazepine acetate (ESL, Aptiom™) is a once-daily anticonvulsant, approved
as adjunctive treatment of partial-onset seizures (POS). Historical-controlled trials …

Background Eslicarbazepine acetate (ESL) is an anticonvulsant approved as an adjunctive
therapy in adults with partial-onset seizures. Objective To evaluate the efficacy, safety and …

Introduction: Eslicarbazepine acetate (ESL) is a third-generation antiepileptic drug (AED)
approved for adjunctive treatment in adults, children, and adolescents with focal-onset …

This study assessed the anticonvulsant and seizure generation effects of carbamazepine
(CBZ), oxcarbazepine (OXC) and eslicarbazepine (S-Lic) in wild-type mice …

Abstract Eslicarbazepine acetate (Aptiom®, Zebinix®) is approved for the adjunctive
treatment of partial-onset seizures in adults aged≥ 18 years. Adjunctive therapy with oral …

Biologically active metabolites are a valuable resource for development of drug candidates
and lead structures for drug design. This digest highlights a selection of biologically active …

Introduction Eslicarbazepine acetate (ESL), together with carbamazepine and
oxcarbazepine, belongs to the dibenzazepine family. According to the latest clinical practice …

Eslicarbazepine acetate (ESL) is a new antiseizure medication (ASM) approved as an
adjunctive therapy or monotherapy for focal onset seizures. We performed this study to …

Given the potential consequences of antiepileptic therapy nonadherence, missed‐dose
scenarios of 12‐to 48‐hour dose delays (4‐hour intervals) for eslicarbazepine acetate …

Objective The aim of the study was to assess the clinical response to eslicarbazepine
acetate (ESL) as add‐on therapy in adult patients with partial‐onset epilepsy by means of …